These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 31167848)

  • 1. "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant
    Zeiser ET; Becka SA; Wilson BM; Barnes MD; LiPuma JJ; Papp-Wallace KM
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of Imipenem-Relebactam against Multidrug- and Extensively Drug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli.
    Becka SA; Zeiser ET; LiPuma JJ; Papp-Wallace KM
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0133221. PubMed ID: 34370574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.
    Papp-Wallace KM; Becka SA; Zeiser ET; Ohuchi N; Mojica MF; Gatta JA; Falleni M; Tosi D; Borghi E; Winkler ML; Wilson BM; LiPuma JJ; Nukaga M; Bonomo RA
    ACS Infect Dis; 2017 Jul; 3(7):502-511. PubMed ID: 28264560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the Potency of β-Lactamase Inhibitors with Diverse Inactivation Mechanisms against the PenA1 Carbapenemase from
    Nukaga M; Yoon MJ; Taracilia MA; Hoshino T; Becka SA; Zeiser ET; Johnson JR; Papp-Wallace KM
    ACS Infect Dis; 2021 Apr; 7(4):826-837. PubMed ID: 33723985
    [No Abstract]   [Full Text] [Related]  

  • 5.
    Van Dalem A; Herpol M; Echahidi F; Peeters C; Wybo I; De Wachter E; Vandamme P; Piérard D
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients.
    Massip C; Mathieu C; Gaudru C; Miaut V; Floch P; Oswald E; Segonds C; Guet-Revillet H
    J Antimicrob Chemother; 2019 Feb; 74(2):525-528. PubMed ID: 30312409
    [No Abstract]   [Full Text] [Related]  

  • 7. Major Aspects of Burkholderia gladioli and Burkholderia cepacia Infections in Children.
    Bedir Demirdag T; Ozkaya Parlakay A; Aygar IS; Gulhan B; Kanik Yuksek S
    Pediatr Infect Dis J; 2020 May; 39(5):374-378. PubMed ID: 32118858
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Mazer DM; Young C; Kalikin LM; Spilker T; LiPuma JJ
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful ceftazidime-avibactam treatment of post-surgery Burkholderia multivorans genomovar II bacteremia and brain abscesses in a young lung transplanted woman with cystic fibrosis.
    Daccò V; Claut L; Piconi S; Castellazzi L; Garbarino F; Teri A; Colombo C
    Transpl Infect Dis; 2019 Jun; 21(3):e13082. PubMed ID: 30892778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility of
    Schaumburg F; Idelevich EA; Mellmann A; Kahl BC
    Microb Drug Resist; 2022 May; 28(5):545-550. PubMed ID: 35512733
    [No Abstract]   [Full Text] [Related]  

  • 11. Comment on: In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients.
    Baklouti S; Massip C; Mane C; Guet-Revillet H; Murris M; Concordet D; Gandia P
    J Antimicrob Chemother; 2019 Oct; 74(10):3122-3123. PubMed ID: 31335940
    [No Abstract]   [Full Text] [Related]  

  • 12. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
    Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Class A β-Lactamase Produced by
    Becka SA; Zeiser ET; LiPuma JJ; Papp-Wallace KM
    Antibiotics (Basel); 2022 May; 11(5):. PubMed ID: 35625319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of ceftazidime/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series.
    Spoletini G; Etherington C; Shaw N; Clifton IJ; Denton M; Whitaker P; Peckham DG
    J Antimicrob Chemother; 2019 May; 74(5):1425-1429. PubMed ID: 30649419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the Role of the Ω-Loop in the Evolution of Ceftazidime Resistance in the PenA β-Lactamase from Burkholderia multivorans, an Important Cystic Fibrosis Pathogen.
    Papp-Wallace KM; Becka SA; Taracila MA; Zeiser ET; Gatta JA; LiPuma JJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examining the activity of cefepime-taniborbactam against
    Mojica MF; Zeiser ET; Becka SA; LiPuma JJ; Six DA; Moeck G; Papp-Wallace KM
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0049823. PubMed ID: 37768313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two case reports of the successful eradication of new isolates of Burkholderia cepacia complex in children with cystic fibrosis.
    Kitt H; Lenney W; Gilchrist FJ
    BMC Pharmacol Toxicol; 2016 Mar; 17():14. PubMed ID: 27018049
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Papp-Wallace KM; Shapiro AB; Becka SA; Zeiser ET; LiPuma JJ; Lane DJ; Panchal RG; Mueller JP; O'Donnell JP; Miller AA
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a Ceftazidime-Avibactam combination in a murine model of Septicemia caused by Enterobacteriaceae species producing ampc or extended-spectrum β-lactamases.
    Levasseur P; Girard AM; Lavallade L; Miossec C; Pace J; Coleman K
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6490-5. PubMed ID: 25136016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis.
    Manno G; Ugolotti E; Belli ML; Fenu ML; Romano L; Cruciani M
    Eur J Clin Microbiol Infect Dis; 2003 Jan; 22(1):28-34. PubMed ID: 12582741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.